Muscular Dystrophy Treatment Market Demand, Key Drivers, Players and Trend Analysis

Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart muscles leading to cardiac problems, and breathing problems. The most common forms of muscular dystrophies include duchenne muscular dystrophy, becker muscular dystrophy, myotonic disease, congenital disease and oculopharyngeal muscular dystrophy. The cure for any form of muscular dystrophy is currently unspecified, but the symptoms can be relived through physical therapy, exercise, rehabilitative devices like a powered wheelchair, respiratory care and surgery.

Request For Sample Copy of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/914

The common muscular dystrophy types:

1. Duchenne muscular dystrophy (DMD)

Most common form of muscular dystrophy in children caused by lack of protein dystrophin. The onset of symptoms is seen at the age of 3, generally wheelchair-bound by 12. The Curvature in spine, heart, and lungs effects are the symptoms. Duchenne muscular dystrophy (DMD) is an X-linked disease predominantly affecting males, resulting in uniform muscle wasting. Death occurs due to respiratory failure by mid-twenties.

1. Becker muscular dystrophy(BMD)

Similar to Duchenne, however, with later onset and slow progression of the illness. Death occurs in the mid-forties.

Molecular therapy segment is expected to generate larger revenue with higher efficiency in clinical trialsThe global muscular dystrophy treatment market is segmented on the basis of treatment, diagnosis, end user and geography.Specific guidance by FDA is expected to dominate North America the global marketRegional segmentation of the global muscular dystrophy treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia-Pacific and The Middle East and Africa. According to the Centers for Disease Control and Prevention estimates in 2007, 349 out of 2.37 million males aged 5 to 24 years were reported to have duchenne muscular dystrophy or becker muscular dystrophy in the United States. North America is expected to dominate the global muscular dystrophy treatment market owing to the absence of marketed pharmacological therapies indicated to treat muscular dystrophy, rising prevalence of the disease and rising research and development for producing effective drugs. Europe is expected to boost the market share in the forecast period with the growing public awareness and increasing research activities.Launch of efficient corticosteroids to rise the market demandThe key players operating the global muscular dystrophy treatment market include Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical, Sarepta Therapeutics and Eli Lilly. The approval and launch of oral corticosteroid Emflaza in 2017, has been found highly effective in patients to regain strength and restore their ability to walk. The other vendors include Acceleron Pharma, Capricor Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer.

Download The PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/914

About Coherent Market Insights:Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702